BioNTech Results Presentation Deck

BNT162b2 Phase 3 trial ြ 7 Vaccinated group ၅၀ ၅၀ ၅၀ ၅၀ Jo Jo Jo 1⁰]⁰]⁰ ြ ြ ၁၅ဝ ၅ဝ၂ဝ၅ဝ BNT 162b2 Up to 44,000 participants 21 days apart Healthy participants 18-85 (+16-17,12-15) yrs of age Active surveillance 7 for potential COVID-19 symptoms TRIGGERING telehealth or in- person visit and nasal swab Number of confirmed COVID-19 cases ≥ day 7 post dose 2 Placebo group ြ oooo ြ ၂၀ ၂၀ ၂၀ ၂၀ ၂၀ ၂၀ Jo Jo Jo Jo Jo Jo Jo Jo Jo Jo Jo Jo Interim analysis of unblinded data by independent data monitoring committee on Nov 8, 2020: 94 disease cases accrued, split of disease cases indicates >90% Vaccine Efficacy Benign safety profile Final efficacy analysis at 164 disease cases expected end of November, 2020 Vaccinated participants will continue to be monitored for up to 2 years C Primary Efficacy Objectives Efficacy against confirmed COVID-19 in participants without evidence of infection before vaccination Efficacy against confirmed COVID-19 in participants with and without evidence of infection before vaccination 43,538 participants enrolled 38,955 received 2nd dose Race/Ethnicity Asian Black Hispanic/Latinx Overall Study 5% 10% 26% Native American Data as of November 08th, 2020 0.8% BIONTECH

View entire presentation